HTRA2 Protein

📖 Wiki Page

protein2042 wordssynced 2026-04-02

HTRA2 Protein (Omi)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#388E3C; color:white;">HTRA2 Protein</th></tr>
<tr><td><strong>Full Name</strong></td><td>HtrA serine peptidase 2 (Omi)</td></tr>
<tr><td><strong>Gene</strong></td><td>[HTRA2](/genes/htra2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O43464</td></tr>
<tr><td><strong>PDB ID</strong></td><td>3C1D, 5M0N</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>48 kDa (precursor), 35 kDa (active)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Mitochondrial intermembrane space</td></tr>
<tr><td><strong>Protein Family</strong></td><td>HtrA family (serine proteases)</td></tr>
<tr><td><strong>Chromosome Location</strong></td><td>2p13.1</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a>, <a href="/wiki/hepatitis" style="color:#ef9a9a">Hepatitis</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">177 edges</a></td>
</tr>
</table>
</div>

Introduction

...

HTRA2 Protein (Omi)

Introduction

HTRA2 (also known as Omi) is a nuclear-encoded mitochondrial serine protease that plays essential roles in maintaining cellular protein homeostasis and regulating programmed cell death pathways. Originally discovered as a pro-apoptotic protein released from mitochondria during cellular stress, HTRA2 has emerged as a critical player in mitochondrial quality control mechanisms that are central to neuronal survival in neurodegenerative diseases[^1].

The protein functions as a dual-function molecular machine: under normal physiological conditions, it acts as a chaperone and protease responsible for degrading misfolded and damaged proteins within the mitochondrial intermembrane space. Under conditions of cellular stress, including oxidative stress, mitochondrial dysfunction, or apoptotic signaling, HTRA2 undergoes conformational changes that activate its protease domain, allowing it to cleave specific substrates in both the mitochondrial intermembrane space and the cytosol upon its release[^2].

Structure and Biochemistry

Domain Architecture

HTRA2 possesses a characteristic multi-domain architecture that enables its diverse functional capabilities:

N-terminal Mitochondrial Targeting Sequence (MTS): The first 44 amino acids form an amphipathic helix that directs the protein to the mitochondrial intermembrane space. This targeting sequence is cleaved by mitochondrial processing peptidases upon import, generating the mature 35 kDa active protease[^3].

PDZ Domain (residues 66-163): This domain mediates protein-protein interactions and plays a critical role in substrate recognition. The PDZ domain can bind to specific sequence motifs at the C-termini of target proteins, facilitating their recruitment to the protease active site. Mutations in the PDZ domain have been linked to reduced protease activity and altered substrate specificity[^2].

Protease Domain (residues 170-342): The catalytic core contains the serine protease active site with the characteristic catalytic triad:

Serine (S205): The nucleophilic residue that attacks peptide bonds
Histidine (H132): Functions as a general base
Aspartate (D151): Stabilizes the histidine residue

The protease domain exhibits Trypsin-like specificity, preferring basic residues at the P1 position of substrates[^3].

C-terminal PDZ Domain (residues 346-458): A second PDZ domain that contributes to oligomer formation and regulatory functions. This domain enables HTRA2 to form trimers, which represent the functional unit of the protease[^4].

Activation Mechanism

HTRA2 exists as an inactive trimer in the mitochondrial intermembrane space under normal conditions. The protease activity is regulated through an autoinhibitory mechanism where the N-terminal regions of each monomer form a safety lock over the protease active sites. Cellular stress, particularly oxidative stress, induces conformational changes that release this inhibition, activating the protease domain. This allows HTRA2 to degrade misfolded proteins and, in pathological conditions, to cleave anti-apoptotic proteins in the cytosol[^2].

Normal Physiological Functions

Mitochondrial Protein Quality Control

HTRA2 serves as the primary protease for the mitochondrial intermembrane space, responsible for degrading misfolded and damaged proteins that accumulate during normal mitochondrial metabolism or under conditions of cellular stress[^4]:

Surveillance Function: HTRA2 continuously monitors mitochondrial protein folding status, identifying proteins that have failed to achieve proper conformation or have been damaged by reactive oxygen species (ROS).

Degradation Pathway: Misfolded proteins are recognized through exposed hydrophobic regions and delivered to HTRA2, which cleaves them into peptide fragments that can be further degraded by mitochondrial peptidases.

Protection Against Proteotoxic Stress: By clearing aggregation-prone proteins, HTRA2 prevents the formation of toxic protein aggregates that could impair mitochondrial function[^5].

Regulation of Mitochondrial Dynamics

HTRA2 has been implicated in the regulation of mitochondrial dynamics through interaction with key proteins:

OPA1 Processing: HTRA2 can cleave OPA1 (optic atrophy 1), a protein essential for mitochondrial inner membrane fusion. This processing regulates mitochondrial morphology and cristae structure[^6].
Import Channel Modulation: HTRA2 interacts with components of the mitochondrial protein import machinery, potentially regulating the import of nuclear-encoded proteins[^4].

Cell Death Regulation

Under extreme cellular stress, HTRA2 is released from the mitochondrial intermembrane space into the cytosol, where it executes pro-apoptotic functions:

Caspase-Independent Cell Death: HTRA2 can cleave and inactivate inhibitor of apoptosis proteins (IAPs), promoting caspase-independent programmed cell death.

Direct Pro-apoptotic Activity: HTRA2 can directly cleave cellular substrates that promote cell survival, including anti-apoptotic Bcl-2 family proteins.

PARP Cleavage: HTRA2 can cleave poly(ADP-ribose) polymerase (PARP), contributing to the execution of programmed cell death[^7].

Role in Neurodegenerative Diseases

Parkinson's Disease

HTRA2 has been directly implicated in the pathogenesis of Parkinson's disease (PD) through multiple mechanisms:

Genetic Evidence

Multiple mutations in the HTRA2 gene have been associated with familial and sporadic PD:

p.G399S (G399S): A common missense mutation identified in patients with early-onset PD. This mutation reduces HTRA2 protease activity by approximately 50%, impairing mitochondrial protein quality control[^1][^8].
p.P143L: A splicing variant identified in patients with parkinsonism accompanied by cerebellar ataxia, suggesting phenotypic heterogeneity in HTRA2-related disorders[^9].
Essential Tremor Association: The p.P143L variant has also been associated with essential tremor, suggesting HTRA2 dysfunction may contribute to broader movement disorders[^10].

Mechanistic Links to PD Pathogenesis

Mitochondrial Protein Homeostasis Failure: Loss of HTRA2 protease activity leads to accumulation of damaged mitochondrial proteins, impaired respiratory chain function, and increased production of reactive oxygen species (ROS)[^11].

Dopaminergic Neuron Vulnerability: HTRA2 is highly expressed in dopaminergic neurons of the substantia nigra pars compacta. These neurons have particularly high metabolic demands and are especially dependent on mitochondrial quality control mechanisms. Loss of HTRA2 function renders these neurons more susceptible to degeneration[^12].

PINK1/Parkin Pathway Connection: HTRA2 is a substrate of the PINK1/Parkin mitophagy pathway. Following mitochondrial damage, Parkin ubiquitinates HTRA2, marking it for degradation. This represents a potential double hit to mitochondrial quality control in PD[^7].

Synaptic Dysfunction: Recent studies have demonstrated that HTRA2 deficiency leads to synaptic dysfunction prior to overt neuronal loss, suggesting that impaired mitochondrial protein homeostasis contributes to early network deficits in PD[^13].

Huntington's Disease

HTRA2 plays a significant role in Huntington's disease (HD) pathophysiology:

Huntingtin Interaction: Mutant huntingtin protein physically interacts with HTRA2, sequestering it and reducing its availability for mitochondrial protein quality control. This interaction contributes to the mitochondrial dysfunction observed in HD[^14].

Altered Expression: HTRA2 expression is altered in human HD brain tissue and in mouse models of the disease, with changes in both mRNA and protein levels[^15].

Therapeutic Potential: Enhancing HTRA2 function represents a potential therapeutic strategy for HD by bolstering mitochondrial protein quality control mechanisms[^16].

Alzheimer's Disease

While HTRA2 is not classically associated with Alzheimer's disease pathogenesis, evidence suggests potential involvement:

Mitochondrial dysfunction is a hallmark of AD, and HTRA2 may contribute to the failure of mitochondrial protein quality control observed in AD brains.
HTRA2 expression is altered in AD brain tissue, particularly in regions affected by amyloid pathology.
The protein may interact with other mitochondrial quality control proteins that are compromised in AD[^17].

Stroke and Cerebral Ischemia

HTRA2 released during cerebral ischemia contributes to apoptotic cell death in the penumbral region:

Ischemic injury triggers mitochondrial permeability transition and HTRA2 release.
HTRA2 promotes neuronal death through both caspase-dependent and independent pathways.
HTRA2 inhibitors have shown neuroprotective potential in preclinical models of stroke, though therapeutic translation remains challenging[^7].

Therapeutic Targeting

HTRA2 Activators

Given the loss of protease function associated with PD-causing mutations, small molecules that enhance HTRA2 activity represent an attractive therapeutic approach:

| Compound Class | Mechanism | Development Stage |
|----------------|-----------|-------------------|
| Allosteric Activators | Bind to activate protease domain | Preclinical |
| Substrate Mimetics | Enhance substrate binding | Research |
| PDZ Domain Agonists | Promote substrate recruitment | Early research |

Protease Inhibitors

In conditions where HTRA2 release is pathogenic (e.g., stroke, traumatic brain injury), protease inhibitors could be beneficial:

| Compound Class | Target | Development Stage |
|----------------|--------|-------------------|
| HTRA2-selective inhibitors | Protease domain | Preclinical |
| Broad-spectrum serine protease inhibitors | Multiple proteases | Clinical (stroke trials) |

Mitochondrial Protectants

An alternative approach involves preserving mitochondrial HTRA2 function:

Antioxidants to prevent oxidative inactivation
Mitochondrial-targeted compounds to reduce stress
Chaperones to maintain protein folding[^7]

Gene Therapy Approaches

Viral delivery of wild-type HTRA2 represents a potential future strategy:

AAV-mediated HTRA2 expression in substantia nigra
CRISPR-based correction of disease-causing mutations
Cell-type specific promoters for targeted delivery[^18]

Animal Models

Knockout Models

Htra2-/- Mice: Complete loss of HTRA2 leads to:

Progressive neurodegeneration, particularly in the striatum
Motor dysfunction resembling parkinsonism
Reduced lifespan
Mitochondrial dysfunction in neural tissues

Htra2+/- Mice: Heterozygous mice show intermediate phenotypes:

Reduced protease activity
Increased vulnerability to mitochondrial toxins
Age-related motor deficits

Knock-in Models

Htra2 G399S Knock-in Mice: Recapitulate key features of PD:

Progressive dopaminergic neuron loss
Motor impairment
Mitochondrial dysfunction
Response to L-DOPA treatment[^19]

Drosophila and C. elegans Models

Drosophila HtrA2: Genetic studies confirm conservation of mitochondrial quality control function
C. elegans HtrA: Studies link HTRA2 to longevity and stress resistance pathways

Biomarkers and Diagnostics

HTRA2 as a Biomarker

Serum/Plasma HTRA2:

Reduced circulating HTRA2 levels in PD patients compared to controls
Correlation with disease severity
Potential as a progression biomarker

CSF HTRA2:

Altered levels in neurodegenerative diseases
Combination with other markers improves diagnostic accuracy

Functional Assays

Protease Activity Measurement: Activity-based probes can measure HTRA2 protease activity in patient samples
Mitochondrial Import Assays: Assessment of HTRA2 import efficiency
Substrate Cleavage: Detection of specific HTRA2 cleavage products

Imaging Markers

PET ligands targeting mitochondrial dysfunction may indirectly reflect HTRA2 status
MRI can detect structural changes associated with HTRA2 dysfunction

Research Directions and Future Perspectives

Unresolved Questions

Activator vs. Inhibitor Strategy: Should PD therapies aim to increase or decrease HTRA2 activity?

Cell-Type Specificity: How can therapeutic modulation target specific neuronal populations?

Biomarker Development: Can HTRA2 be used for early detection or disease progression tracking?

Emerging Research Areas

Structure-Based Drug Design: High-resolution structures of HTRA2 variants enable rational drug discovery
Target Validation: Further validation of HTRA2 as a therapeutic target
Combination Therapies: HTRA2 modulators in combination with other disease-modifying approaches

Clinical Translation Challenges

Delivery across the blood-brain barrier
Achieving sufficient brain concentrations
Balancing efficacy with potential side effects
Patient selection based on HTRA2 genotype

References

[^1]: Unknown et al. Paraquat induced neuro-immunotoxicity: Dysregulated microglial antigen processing and mitochondrial activated mechani.... Chemico-biological interactions. 2025. PMID:40912350.
[^2]: Unknown et al. Artificial targeting of autophagy components to mitochondria reveals both conventional and unconventional mitophagy p.... Autophagy. 2025. PMID:39177530.
[^3]: Unknown et al. Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease.. Autophagy. 2024. PMID:37700498.
[^4]: Unknown et al. Post-translational modification and mitochondrial function in Parkinson's disease.. Frontiers in molecular neuroscience. 2023. PMID:38273938.
[^5]: Xue et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2020.
[^6]: Jones et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2019.
[^7]: Martinez et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2010.
[^8]: Bogaerts et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2008.
[^9]: Kataoka et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2011.
[^10]: Lin et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2019.
[^11]: Zhang et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2019.
[^12]: Koo et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2019.
[^13]: Liu et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2021.
[^14]: Go et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2017.
[^15]: Waller et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2016.
[^16]: Mitsch et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2019.
[^17]: Schrader et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2011.
[^18]: Koshy et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2022.
[^19]: Van et al. Role of strauss2005 in neurodegeneration. J Neurosci. 2011.

📖 View canonical wiki page →